Stable-Phase Peyronie’s Disease: Have Perilesional Injections of Hyaluronic Acid Come of Age?
Open Access
- 31 August 2026
- journal article
- research article
- Published by MDPI AG in Clinics and Practice
- Vol. 16 (9) , 162
Abstract
Background: Peyronie’s Disease (PD) is a complex andrological condition that severely compromises patients’ quality of life. While a novel formulation of hyaluronic acid (HA) has recently gained traction for treating the acute inflammatory phase, clinical evidence regarding its role in stable-phase (chronic) PD is lacking. We aimed to assess the therapeutic outcomes and safety profile of Perovial®, a specialized HA formulation, in patients with stable disease. Methods: A cohort of 47 patients with stable-phase PD was treated at a single andrological center between June and December 2025. The treatment protocol consisted of eight weekly injections targeted around the tunica albuginea plaque. Clinical efficacy was assessed 3 months post-treatment by comparing baseline data with the following outcome measures: change in penile curvature (Δ°), the international index of erectile function (IIEF-5) score, Peyronie’s Disease Questionnaire (PDQ) and Global Assessment of Peyronie’s Disease (GAPD). Results: At the 3-month follow-up visit, a statistically significant improvement in penile curvature was registered in 35 out of 47 patients (Δ° − 16) (p < 0.001). All patients had a significant improvement from baseline in terms of IIEF (20 vs. 24; p < 0.001) and in all PDQ domains. No major adverse events or complications were observed during the study period. At the GAPD questionnaire, 43 patients (91.2%) reported subjective improvement of penile curvature. Conclusions: Perilesional injection of Perovial® seems a promising intervention in patients with stable-phase PD in terms of penile curvature reduction and patient-reported quality of life improvement.Keywords
This publication has 18 references indexed in Scilit:
- Targeting the acute phase of Peyronie’s disease: preliminary experience with Perovial®, a novel hyaluronic acid formulationInternational Journal Of Impotence Research, 2025
- Injection therapy in the acute phase of Peyronie’s disease: a systematic review of current evidenceThe Journal of Sexual Medicine, 2025
- Incremental Treatment Response by Cycle With Collagenase Clostridium Histolyticum for Peyronie's Disease: A Pooled Analysis of Two Phase 3 TrialsUrology, 2023
- Surgical Reconstruction of Penile Curvature due to Peyronie’s Disease by Plaque Incision and Buccal Mucosa GraftThe Journal of Sexual Medicine, 2021
- Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s DiseaseSexual Medicine Reviews, 2019
- Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot StudySexual Medicine, 2016
- Self-report and Clinical Response to Peyronie's Disease Treatment: Peyronie's Disease Questionnaire Results From 2 Large Double-Blind, Randomized, Placebo-Controlled Phase 3 StudiesUrology, 2015
- Bother and Distress Associated with Peyronie's Disease: Validation of the Peyronie’s Disease QuestionnaireJournal of Urology, 2013
- Diagnostic evaluation of the erectile function domain of the international index of erectile functionUrology, 1999
- The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunctionUrology, 1997